OXFORD BIOMEDICA PLC

Oxford Biomedica shares climb 1.15 % as the company’s gene‑therapy focus gains momentum, driving a 6.9 % rise and outpacing peers in London’s biotech sector.

Oxford Biomedica (OXB.L) boosts biotech outlook, trading at GBX 524.95 with a 6.9% month‑end rise; explore its FDA‑approved lentiviral platform and partnership pipeline.

Oxford Biomedica shares climb 0.39 % to GBX 521 in a 24‑hour rally, amid broader market moves and its biotech focus on lentiviral gene therapy.